Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

ningbo riway industrial co., ltd. - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - antibacterial for body cleaning to decrease bacteria on skin. do not use in eyes.in case of contact,rinse thoroughly with water. stop use and ask doctor if rash/redness or irritation appears/develops and persist for more than 72 hours.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

chartwell rx, llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters capsules are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg/dl) hypertriglyceridemia. usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules and should continue this diet during treatment with omega-3-acid ethyl esters capsules. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of tg-lowering drug therapy. limitations of use: the effect of omega-3-acid ethyl esters capsules on the risk for pancreatitis has not been determined. the effect of omega-3-acid ethyl esters capsules on cardiovascular mortality and morbidity has not been determined. omega-3-acid ethyl esters capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters capsules or any of its components. risk summary the available data from published case reports and the pharmacovigilance database on the use of omega-3-acid ethyl esters in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development when given at doses 5 times the maximum recommended human dose (mrhd) of 4 grams/day, based on a body surface area comparison. omega-3-acid ethyl esters given orally to rats and rabbits during organogenesis was not teratogenic at clinically relevant exposures, based on body surface area comparison (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data: in female rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) beginning 2 weeks prior to mating through lactation, no adverse effects were observed at 2,000 mg/kg/day (5 times the mrhd based on body surface area [mg/m 2 ]). in a dose-ranging study, female rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) beginning 2 weeks prior to mating through postpartum day 7 had decreased live births (20% reduction) and pup survival to postnatal day 4 (40% reduction) at or greater than 3,000 mg/kg/day in the absence of maternal toxicity at 3,000 mg/kg/day (7 times the mrhd based on body surface area [mg/m 2 ]). in pregnant rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses at a maternally toxic dose (increased food consumption) of 6,000 mg/kg/day (14 times the mrhd based on body surface area [mg/m 2 ]). in pregnant rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) from gestation day 14 through lactation day 21, no adverse effects were observed at 2,000 mg/kg/day (5 times the mrhd based on body surface area [mg/m 2 ]). in pregnant rabbits given oral doses of omega-3-acid ethyl esters (375, 750, or 1,500 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses given 375 mg/kg/day (2 times the mrhd based on body surface area [mg/m 2 ]). however, at higher doses, increases in fetal skeletal variations and reduced fetal growth were evident at maternally toxic doses (reduced food consumption and body weight gain) greater than or equal to 750 mg/kg/day (4 times the mrhd), and embryolethality was evident at 1,500 mg/kg/day (7 times the mrhd). risk summary published studies have detected omega-3 fatty acids, including epa and dha, in human milk. lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk. there are no data available on the effects of omega­3 fatty acid ethyl esters on the breastfed infant or on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for omega-3-acid ethyl esters and any potential adverse effects on the breastfed child from omega-3-acid ethyl esters or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. a limited number of subjects older than 65 years were enrolled in the clinical trials of omega-3-acid ethyl esters. safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

omegapharm - thiopental sodium, quantity: 470 mg - injection, powder for - excipient ingredients: - ? as the sole anaesthetic agent for brief surgical procedures.,? induction of anaesthesia prior to the administration of other anaesthetic agents.,? short-term control of convulsive states.,? supplement to regional anaesthesia or low potency agents such as nitrous oxide.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - ascorbic acid,colecalciferol,cyanocobalamin,dl-alpha-tocopheryl acetate,folic acid,lysine hydrochloride,nicotinamide,pyridoxine hydrochloride,retinol acetate,riboflavine,thiamine hydrochloride -

Austraalia - inglise - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - recombinant omega interferon of feline origin - parenteral liquid/solution/suspension - recombinant omega interferon of feline origin vaccine active 10.0 mu/ml - immunotherapy - cat | dog - adult | cat - queen | cat - tom | kitten - canine parvovirus | feline calicivirus | calicivirus (feline) | fcv | parvovirus

Iisrael - inglise - Ministry of Health

abbott medical laboratories ltd, israel - omega-3 acid ethyl esters - capsules - omega-3 acid ethyl esters 1000 mg - omega-3-triglycerides - omega-3-triglycerides - post myocardial infarction: adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet drugs, betablockers, ace inhibitors). hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: - type iv hypertriglyceridaemia. - type iib/iii hypertriglyceridaemia in combination with statin, when control of triglycerides by statins is insufficient.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - zinc sulfate monohydrate, quantity: 20.6 mg (equivalent: zinc, qty 7.5 mg); cupric sulfate pentahydrate, quantity: 3.928 mg (equivalent: copper, qty 1 mg); manganese sulfate monohydrate, quantity: 5.539 mg (equivalent: manganese, qty 1.8 mg); dried magnesium sulfate, quantity: 317.46 mg (equivalent: magnesium, qty 40 mg); borax, quantity: 2.205 mg (equivalent: boron, qty 0.25 mg); calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600 mg); colecalciferol, quantity: 0.005 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; magnesium stearate; maltodextrin; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified talc; allura red ac; polyvinyl alcohol; macrogol 3350; lecithin; maize starch; acacia; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides; polysorbate 80; macrogol 4000 - maintain/support bone health ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

alissa healthcare research ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - riboflavine, quantity: 0.25 mg; nicotinamide, quantity: 2.5 mg; colecalciferol, quantity: 0.0025 mg; ascorbic acid, quantity: 50 mg; lysine hydrochloride, quantity: 50 mg; thiamine hydrochloride, quantity: 0.25 mg; pyridoxine hydrochloride, quantity: 0.25 mg (equivalent: pyridoxine, qty 205 microgram); cyanocobalamin, quantity: 2 microgram; folic acid, quantity: 250 microgram; dl-alpha-tocopheryl acetate, quantity: 10 mg; retinol acetate, quantity: 0.5307 mg - tablet, chewable - excipient ingredients: maltodextrin; glucose monohydrate; magnesium stearate; sucralose; hypromellose; colloidal anhydrous silica; calcium hydrogen phosphate dihydrate; maize starch; acacia; dl-alpha-tocopherol; spray-dried glucose syrup; silicon dioxide; flavour; sucrose; medium chain triglycerides; colour - maintain/support healthy appetite ; enhance/improve/promote/increase nutrient uptake ; enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body